TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05266001
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: same as arm/group description
Study: NCT05810870
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate (eribulin), a non-taxane inhibitor of microtubule dynamics of the halichondrin class of antineoplastics, suppresses microtubule growth and sequesters tubulin into nonfunctional aggregates, preventing mitotic spindle formation with subsequent G2-M stop and apoptosis.
Study: NCT06470243
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06470243
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06470243
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06449001
Drug: Danicopan
Normalized name: Danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive danicopan on a weight-based dosing regimen.
Study: NCT06335888
Drug: AzaFol
DrugBank: 10-formyl-5,8,10-trideazafolic acid (DB02540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AzaFol-PET/CT imaging
Study: NCT06335888
Drug: FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDG-PET/CT imaging
Study: NCT06177067
Drug: Revumenib
Normalized name: Revumenib
DrugBank: Revumenib (DB18515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth (capsule or liquid solution) or liquid solution by Nasogastric tube (NG) or Gastrostomy tube (G-tube)
Study: NCT06177067
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by mouth (tablet)
Study: NCT06177067
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously (IV) infusion
Study: NCT06177067
Drug: intrathecal (IT) chemotherapy
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intrathecal (IT)
Study: NCT06177067
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
Study: NCT06400615
Drug: AD109
Normalized name: Adefovir dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration at bedtime
Study: NCT05825495
Drug: Dinalbuphine sebacate
Normalized name: Dinalbuphine sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 150 mg dinalbuphine sebacate will be intragluteally administrated at least 12 hours before surgery.
Study: NCT05339100
Drug: Anifrolumab
Normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive SC doses anifrolumab via AI or APFS.
Study: NCT05832047
Drug: Lactated Ringer solution (4-hour aggressive hydration)
Normalized name: lactate
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.
Study: NCT05832047
Drug: 8-hour aggressive hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If patients experienced postprocedural abdominal pain Numerical Rating Scale (NRS score\>3) or a worsening of abdominal pain compared with the pain before ERCP, the administration of study fluid continues until 8 hours (3 mL/kg/hr ) regardless of the results of serum amylase/lipase within 4 hours after ERCP because serum amylase/lipase within 4 hours after ERCP may have a result approximately 1-2 hours (5 hours-6 hours after ERCP) after blood sampling
Study: NCT06233266
Drug: Ticagrelor-Test product
Normalized name: ticagrelor Oral Product
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor Tablets 90 mg Manufactured by: Mankind Pharma Limited, India
Study: NCT06233266
Drug: Ticagrelor-Reference product
Normalized name: ticagrelor Oral Product
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor Tablets 90 mg Manufactured by: AstraZeneca AB, Sweden
Study: NCT05962957
Drug: carbidopa-levodopa
Normalized name: Carbidopa-Levodopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levodopa is typically prescribed to a patient with Parkinson disease once symptoms become more difficult to control with other anti-parkinsonism drugs. The drug can also be used for postencephalitic parkinsonism and symptomatic parkinsonism due to carbon monoxide intoxication
Study: NCT05962957
Drug: Pentoxifylline 400 MG
Normalized name: pentoxifylline 400 MG
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy via suppression of the TLR4/NF-κB network signaling pathway. Moreover, Pentoxifylline has a potential antioxidant capacity mostly via nuclear erythroid 2-related factor 2 (Nrf2) activation with subsequent up-regulation and expression of several antioxidant enzymes
Study: NCT05075564
Drug: Part 1 ES002023
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Study: NCT06334198
Drug: Naldemedine
Normalized name: Naldemedine
DrugBank: Naldemedine (DB11691)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Naldemedine is administered orally once daily in the morning in a dosage of 0.2 mg.
Study: NCT05075564
Drug: Part 2 ES002023
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Study: NCT05332561
Drug: Atezolizumab 1200 mg in 20 ML Injection
Normalized name: atezolizumab 1200 MG in 20 ML Injection
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm 1
Study: NCT05332561
Drug: Inavolisib
Normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2
Study: NCT05332561
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 3
Study: NCT05332561
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm 4
Study: NCT05332561
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arm 5
Study: NCT05332561
Drug: Trastuzumab/pertuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm 6
Study: NCT06168734
Drug: Cefepime-taniborbactam
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefepime-taniborbactam administered 2.5g q8h intravenously (IV) over a 4-hour period for 7 days to 14 days at the investigator's discretion. Dose adjustments for renal function may apply.
Study: NCT06168734
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem will be administered 2g q8h IV over 4 hours for 7 days to 14 days at the investigator's discretion. Dose adjustments for renal function may apply.
Study: NCT06666335
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous injections once daily for 6 months
Study: NCT05152628
Drug: Tacrolimus granules
Normalized name: tacrolimus Granules for Oral Suspension
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT05338606
Drug: Bimatoprost Sustained Release Implant
Normalized name: bimatoprost Drug Implant
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intraocular Implant
Study: NCT05491083
Drug: Pembrolizumab & ADG106 (Phase Ib)
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes
Study: NCT05491083
Drug: Pembrolizumab & ADG106 (Phase II)
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes
Study: NCT05705492
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06585449
Drug: ALN-HTT02
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN-HTT02 will be administered intrathecally
Study: NCT06317311
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is administered IV at a dose of Area under the concentration time curve (AUC) 5 milligram\*millilitre/ minute (mg•mL/min) for cycles 1 to 6 (each cycle is of 21 days)
Study: NCT06317311
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel is administered IV at a dose of 175 milligram per meter square (mg/m2) for cycles 1 to 6 (each cycle is of 21 days)
Study: NCT06149663
Drug: LP352
Normalized name: Linzagolix
DrugBank: Linzagolix (DB17083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP352 will be administered as a liquid either orally or through a G-tube or Percutaneous Endoscopic Gastrotomy (PEG) tube.
Study: NCT04961996
Drug: Giredestrant
Normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
Study: NCT04961996
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib 150 mg will be administered orally (PO) twice a day (BID) on Days 1-28 during each 28-day cycle for 2 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
Study: NCT06334198
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In both arms, tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200mg).
Study: NCT04985955
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib tablet will be administered orally.
Study: NCT04345913
Drug: Copanlisib Hydrochloride
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04345913
Drug: Eribulin Mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT05383196
Drug: Onvansertib
Normalized name: Onvansertib
DrugBank: Onvansertib (DB15110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, once daily for 21 consecutive days, followed by 7 days without drug, to complete a cycle of 28 days.
Study: NCT05383196
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: once a week into your vein (by intravenous infusion) over about 30 minutes. This will continue for 3 weeks of every cycle
Study: NCT00000869
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06431893
Drug: Pegtibatinase
Normalized name: Pegtibatinase
DrugBank: Pegtibatinase (DB17677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full Target Dose of pegtibatinase BIW
Study: NCT06469281
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT06469281
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Infusion
Study: NCT05633654
Drug: Sacituzumab govitecan-hziy (SG)
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT05633654
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT05750589
Drug: IRX-101
Normalized name: IRX-2
DrugBank: IRX-2 (DB05643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRX-101 is a novel ocular anti-septic
Study: NCT05750589
Drug: Providone-Iodine
Normalized name: POVIDONE-IODINE 12 g TOPICAL SWAB [PROVIDONE-IODINE PREP PADS]
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% Providone-Iodine
Study: NCT04971551
Drug: Jaktinib Hydrochloride Tablets
Normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral on an empty stomach
Study: NCT05279027
Drug: Zirconium Zr 89 Crefmirlimab Berdoxa
Normalized name: ZIRCONIUM ZR 89 CREFMIRLIMAB BERDOXAM
DrugBank: Crefmirlimab (DB17577)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT scans pre and post therapy initiation
Study: NCT05852847
Drug: Baricitinib 2 MG [Olumiant]
Normalized name: baricitinib 2 MG [Olumiant]
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral baricitinib was given at a dose of 2 mg daily for 6 months. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patients' request.
Study: NCT05852847
Drug: Danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol was given at a dose of 200 mg bid for 6 months
Study: NCT01215890
Drug: risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00046267
Drug: Niacin
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06547216
Drug: AOC 1020
Normalized name: AOC-1020
DrugBank: AOC-1020 (DB18621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOC 1020 will be administered via intravenous (IV) infusion
Study: NCT05739045
Drug: nivolumab combined with SOX
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nivolumab + SOX (3 cycles) before surgery → radical surgery (D2) → nivolumab + SOX (3 cycles) after surgery → nivolumab monotherapy maintenance (11 cycles);
Study: NCT06692283
Drug: denifanstat
Normalized name: Denifanstat
DrugBank: Denifanstat (DB17576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT06799065
Drug: ATX-295
Normalized name: ATX-01
DrugBank: ATX-01 (DB18141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATX-295 Tablets will be taken orally
Study: NCT05719441
Drug: ART
Normalized name: MART1
DrugBank: Melanoma antigen recognized by T-cells 1 (DB15081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food
Study: NCT06169527
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dupilumab cohort
Study: NCT05928780
Drug: B2:SG
Normalized name: Betamethasone Sodium Gluconate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SG 10mg/kg， d1, 8
Study: NCT05928780
Drug: D2:SG
Normalized name: Dextrose 2% in Sodium Chloride 0.9%
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SG 10mg/kg d1, 8
Study: NCT05733780
Drug: Prolectin-M
Normalized name: Prolectin-M
DrugBank: Prolectin-M (DB16521)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolectin-M~Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
Study: NCT06429761
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion Trastuzumab deruxtecan will be administered at 5.4 mg/kg on day 1 of a 21 day cycle for 9 cycles.
Study: NCT00007436
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00324909
Drug: Hyperbaric Oxygen Therapy
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05455294
Drug: Navitoclax
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm Description
Study: NCT05455294
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: See Arm Description
Study: NCT05455294
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Arm Description
Study: NCT05695352
Drug: Levonorgestrel 1.5mg
Normalized name: LEVONORGESTREL 1.5MG TAB
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral synthetic progesterone agonist
Study: NCT04966481
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered on an outpatient basis
Study: NCT04966481
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously over approximately 60 minutes
Study: NCT06165900
Drug: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab plus radiotherapy phase: radiotherapy was started on the day of the second cycle of adebrelimab administration every other day for 3 fractions; Adebrelimab plus chemotherapy phase: starting within 3-5 weeks after completion of radiotherapy, every 3 weeks for 6 cycles.
Study: NCT06165900
Drug: adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
Normalized name: Carboplatin
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
Study: NCT04338126
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: previously described
Study: NCT06068465
Drug: pimavanserin tartrate
Normalized name: Pimavanserin tartrate
DrugBank: Pimavanserin (DB05316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks
Study: NCT04871529
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04871529
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04871529
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06667037
Drug: 0.01% Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.01% Atropine will be administrated twice a day with an interval of about 12 hours. Drop into the conjunctival sac and immediately compress the lacrimal sac of the inner canthus for 2-3 minutes.
Study: NCT04321551
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1- ylmethylene)dibenzonitrile. Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water. It has a molecular weight of 285.31, empirical formula C17H11N5, and a melting range of 184°C to 185°C. Letrozole is available as 2.5 mg tablets for oral administration.
Study: NCT04842045
Drug: Psilocybin and Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.~The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight.
Study: NCT05554822
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single antiplatelet therapy with aspirin 100 mg OD for 6 months after the procedure
Study: NCT05554822
Drug: Aspirin 100 mg OD plus clopidogrel 75 mg OD
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Double antiplatelet therapy with Aspirin 100 mg OD plus clopidogrel 75 mg OD for 3 months, followed by 3 months of single antiplatelet therapy with aspirin 100 mg OD.
Study: NCT05996406
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax 400mg po qd for 1 year
Study: NCT05996406
Drug: Dexamethasone Oral
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40mg po qw for the first 6 months, then 10mg po qw for the next 6 months
Study: NCT04696055
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 400 mg to be administered as an intravenous (IV) infusion every 6 weeks (Q6W).
Study: NCT04696055
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib to be given orally (p.o.) at a starting dose of 90 mg QD for 3 weeks of every 4 weeks (i.e., 3 weeks on, 1 week off). If the starting dose of 90 mg daily is well tolerated the dose should be escalated to 120 mg starting after the first 4-week cycle of regorafenib.